Psilocybin and the Next Generation of Mental Health Professionals

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Interest from students and early career clinicians in psilocybin is rising in the United States, and there are clear steps they can take to prepare for research and future clinical work within current rules. Training spans core mental health education, controlled substance operations, therapist competencies for session support, and participation in federally regulated studies that follow FDA, DEA, and IRB guidance.

Interest from students and early career professionals

Students in medicine, psychology, nursing, social work, and pharmacy are asking how to gain credible experience with psilocybin today. The most direct path is to join active research programs that operate under federal oversight. These teams offer exposure to protocol design, consent and safety planning, and session day logistics. Trainees who help with rating scales, visit coordination, and research pharmacy intake learn habits that carry into more senior roles.

The draw is both scientific and clinical. On the science side, trainees see how protocols link dose, support models, and outcome measures. On the clinical side, they learn how hospitals prepare rooms, set observation windows, and document care during long sessions. This mix builds practical judgment that general coursework rarely covers.

Students also want clarity on the difference between service programs in a few states and FDA regulated trials. Camps that separate these paths early tend to avoid confusion when trainees discuss ethics, consent, and risk management. The safest approach is to treat service models and research as different systems with different rules, then teach each on its own terms.

Training pathways for psychiatry, psychology, and pharmacology

Training for psilocybin work sits on top of core disciplines. The steps below map to skills that research teams in hospitals expect from early career staff.

Psychiatry
Residents can rotate through trials that study depression, anxiety, oncology distress, or addiction. Core skills include diagnostic assessment, medication review, and acute support for distress during sessions. Residents learn to work with therapists who deliver preparatory and integration visits. Many programs add seminars on session documentation, vital sign thresholds for intervention, and collaboration with research pharmacies.

Psychology
Graduate students and interns can focus on assessment, psychotherapy models, and outcome measures. Trials need trained raters who can administer scales with reliability. They also need therapists who can deliver manualized support before, during, and after sessions. Supervision and case review meetings help maintain quality across teams. Students learn to record observations in language that fits both clinical care and audit trails.

Pharmacy
Students and residents in pharmacy help set up receipt, storage, and accountability for Schedule I products. They learn to check labels, log kit IDs, download temperature data, and reconcile counts after visits. When dose forms are simple, such as fixed strength capsules or tablets, pharmacy work focuses on clean intake and careful issue of kits based on the randomization plan. Training also covers destruction with witnesses at study end.

Nursing and allied health
Nurses, physician assistants, and occupational therapists contribute to observation and safety tasks. They monitor vital signs, document status at defined intervals, and coordinate with therapists during sessions. Short job aids at workstations help new staff follow steps without error. These roles often anchor long session days and set the tone for patient comfort and safety.

Data science and biostatistics
Trials need help with instrument selection, data pipelines, and analysis plans. Students in biostatistics or informatics can work on eCRF builds, query resolution, and data quality checks. When imaging or EEG is part of a protocol, technical support teams schedule scans and align timing with dose windows.

Educational programs and certifications emerging

Universities and medical centers are building short courses and certificates that fit around clinical training. Good programs share a few traits. They teach the difference between FDA regulated research and state service models. They cover consent, confidentiality, and safety in a way that aligns with IRB language. They give trainees time in a simulation room to practice roles during a mock session day. They explain how research pharmacies handle Schedule I intake, storage, and reconciliation.

Therapist training modules focus on preparation and integration skills, rapport building, and documentation that matches protocol manuals. Supervision models help keep practice aligned across different therapists and sites. Programs that pair workshops with supervised clinical hours tend to produce stronger outcomes in trials.

Pharmacy and operations modules focus on intake checklists, temperature control, chain of custody, and accountability. These courses often use case studies drawn from oncology or infectious disease trials where similar controls apply. When students practice downloading data from temperature loggers or reconciling kit counts, they build confidence that carries into audits.

As programs grow, cross campus options are forming. A medical school may host therapist seminars while a pharmacy school runs intake labs, and a public health program covers ethics and data governance. Short, stackable offerings help trainees from different backgrounds assemble a complete skill set without adding a year to their degrees.

Role of research internships and partnerships

Internships turn interest into working habits. A strong placement puts a student inside a team that runs live protocols with clear supervision. The best internships assign real tasks that introduce responsibility without outpacing competence.

Research pharmacies
Interns can assist with receipt and kit logging under a licensed pharmacist. They learn to verify permit information, inspect seals, check labels, and file temperature reports. They also see how accountability ties kit IDs to subjects and visits.

Clinical teams
Trainees can help with scheduling, room setup, and patient flow on session days. They can shadow therapists during preparation and integration visits, take part in case reviews, and learn how to document in a way that supports both care and audits. They can also assist with safety tasks such as vital sign checks and recovery monitoring.

Data and methods
Students can work in data cores to build eCRFs, clean data, and prepare queries for sites. Those with interest in analytics can help plan interlab comparisons for psilocybin and psilocin assay methods. Imaging labs can host interns who learn timing and quality checks for fMRI runs linked to dosing windows.

External partners
Hospitals often coordinate with CROs, couriers, and suppliers. Interns who sit in on planning calls learn how shipment memos mirror permits, how kit maps align with randomization, and how resupply is triggered by inventory counts and expiry windows. As suppliers, we often join pharmacy intake rehearsals and permit planning calls, which gives interns a window into controlled logistics and document control.

Mentorship
Pair each intern with a mentor who meets on a set schedule. Mentors help frame what the intern is seeing, answer questions about scope of practice, and set goals for the next month. A written plan makes the internship more than a shadowing experience.

Barriers to entry and ethical considerations

Psilocybin work sits inside tight rules. Barriers often reflect safety and governance, not a lack of interest.

Limited seats
Trials run with small teams and defined therapist ratios. Not every student can sit in on sessions. Programs that create structured rotations for intake, data, and logistics can include more trainees without overloading therapy rooms.

Scope of practice
Students must work inside their license or trainee role. They can help with logistics and data, assist with rating scales under supervision, and learn session support skills through observation and structured practice. Direct clinical activities stay under trained supervisors.

Time and funding
Session days are long. Stipends or hourly pay help students cover time that cannot be split with other jobs. Grants that include trainee support can widen access and reduce drop off.

Ethics and boundaries
Trainees need clear rules for confidentiality, touch boundaries, dual relationships, and social media. They should learn how to debrief after sessions, how to escalate concerns, and how to care for their own mental health when working with intense material. Faculty should model language that is clear and respectful in both clinical notes and research records.

Equity and access
Recruitment and training should seek diversity in background and perspective. Programs can partner with community clinics and veteran groups to build trust. Trainees should learn how to discuss study access and support with patients who face housing, transport, or caregiving barriers.

Data integrity
Students who touch data must understand audit trails, version control, and blinding. They should never move files to personal devices or unapproved drives. Simple checklists for file handling and blinding language reduce accidental leaks.

Public communication
Interest in psychedelics draws media attention. Trainees should route inquiries to study leads and avoid public claims about efficacy or safety. Internal guidelines for presentations, posts, and interviews reduce risk of misinterpretation.

Preparing the next wave of clinical leaders

Preparing future leaders means building habits that last. Programs that train students to document clearly, to run checklists without cutting corners, and to respect roles will produce clinicians who keep trials on track and patients safe.

Start with foundations
Teach the differences between FDA trials and state service models. Explain how IRB, DEA, and FDA oversight intersect. Walk through a real protocol from consent to closeout so students see how decisions ripple through pharmacy, therapy, and data.

Use hands on practice
Run mock receipts with pilot kits. Practice kit logging, temperature downloads, and reconciliation. Simulate a full session day with room setup, safety checks, and handoffs. Use debriefs to set learning points and capture improvements.

Build supervision structures
Therapist training benefits from regular case reviews and observation with feedback. Pharmacy students grow faster when a preceptor reviews intake logs and reconciliation with them. Data interns improve with clear coding standards and peer checks.

Publish practical tools
Checklists, room setup guides, intake templates, and binder maps travel well between sites. Boston and Worcester programs already share these tools across hospitals. Other regions can do the same, which lifts quality and shortens start up.

Link training to real roles
Measure success by how many trainees move into coordinator, rater, therapist, pharmacist, or data roles on active trials. Track how often mock runs prevent intake errors. Gather feedback from auditors and monitors on trainee contributions to clean files.

Keep ethics at the center
Teach humility with claims, respect for consent, and care for confidentiality. Make space for debriefs, supervision, and mental health support for staff. Ethics is not a module. It is a practice that runs through each step of the work.

The next generation will inherit complex programs that require steady hands in clinics, pharmacies, and data rooms. Students who learn within regulated trials develop a track record with controlled deliveries, chain of custody, blinding, and audit habits. With that training, they will be ready to lead clinical teams as evidence grows and care pathways take shape under clear rules.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.